1. Home
  2. CRCT vs CGEM Comparison

CRCT vs CGEM Comparison

Compare CRCT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cricut Inc.

CRCT

Cricut Inc.

HOLD

Current Price

$4.08

Market Cap

857.6M

Sector

Industrials

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.42

Market Cap

794.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRCT
CGEM
Founded
1969
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.6M
794.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CRCT
CGEM
Price
$4.08
$14.42
Analyst Decision
Strong Sell
Strong Buy
Analyst Count
2
9
Target Price
$3.50
$30.11
AVG Volume (30 Days)
600.2K
749.6K
Earning Date
03-03-2026
03-10-2026
Dividend Yield
23.00%
N/A
EPS Growth
20.69
N/A
EPS
0.35
N/A
Revenue
$708,780,000.00
N/A
Revenue This Year
$0.08
N/A
Revenue Next Year
$0.98
$79.85
P/E Ratio
$11.81
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.92
$5.68
52 Week High
$7.33
$16.74

Technical Indicators

Market Signals
Indicator
CRCT
CGEM
Relative Strength Index (RSI) 40.66 55.91
Support Level $3.92 $11.43
Resistance Level $4.57 $16.74
Average True Range (ATR) 0.12 0.86
MACD 0.02 -0.18
Stochastic Oscillator 47.83 50.75

Price Performance

Historical Comparison
CRCT
CGEM

About CRCT Cricut Inc.

Cricut Inc designs and builds a creativity platform that enables users to turn ideas into professional-looking handmade goods. With its connected machines, design apps and accessories, and materials, the users create everything from personalized birthday cards, mugs and T-shirts to large-scale interior decorations. It has two segments including the Platform segment which derives revenue from monthly and annual subscription fees, purchases of digital content, and a minimal amount of the revenue allocated to unspecified future upgrades and enhancements related to the essential software and access to the Company's cloud-based services and Products segment which derives revenue from the sale of its connected machine hardware, and sale of craft, DIY, home decor products and extensions.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: